Global Flow Cytometry Market by Product Type (Instrument, Kit and Reagent), By Technology (Cell-Based Cytometry and Bead-Based Cytometry), By End-User (Hospitals and Clinics, Academic and Research Institutes), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032
- Published date: Oct 2023
- Report ID: 28460
- Number of Pages: 260
The global flow cytometry market size is expected to be worth around USD 104.4 Billion by 2032 from USD 51.6 Billion in 2022, growing at a CAGR of 7.5% during the forecast period from 2022 to 2032.
The outflow of cell surface and intracellular particles, describing and defining various cell types in a heterogeneous cell population, determining the value of isolated subgroups, and breaking down cell size and volume are all aspects of flow cytometry, a generally complex procedure. It enables simultaneous multiparameter examination of individual cells. It is used to distinguish proteins and ligands that bind to specific cell-related atoms, such as propidium iodide restricting to DNA, using fluorescence power generated by fluorescent-named antibodies.
The procedure begins with the staining method, which is followed by the hatching of the cells into microtiter plates or tubes using antibodies that are either fluorochrome-marked or unlabeled, and the examination is carried out using a stream cytometer. Additionally, it is anticipated that an increase in disease and HIV rates will support the flow cytometry market share.
However, the market is expected to be hampered by factors such as the high cost of instruments and reagents, a lack of understanding among potential customers, and limited access to specialized expertise. The application of stream cytometry in drug discovery, diagnostics, and development is intended to boost the flow cytometry market.
- The global flow cytometry market is expected to reach USD 104.4 billion by 2032.
- The flow cytometry market is growing at a CAGR of 7.5%.
- The instrument segment held 37% of the market share in 2022.
- The bead-based flow cytometry segment is growing at a CAGR of 79.30%.
- North America dominated the market with a 40.7% revenue share in 2022.
- Europe held a 32% revenue share in 2022.
- Asia-Pacific is expected to have the highest CAGR.
- The increase in the geriatric population is driving market growth.
- Technological advances in chronic disease treatment are boosting the market.
- Cost-effectiveness is increasing demand for flow cytometry devices.
- Stem cell research and clinical trials contribute to market growth.
- Hospitals and clinics are the dominant end-users of flow cytometry.
- The instrument segment is the most dominant product type in the market.
- Bead-based flow cytometry is the dominant technology due to its advantages.
- Lack of technological awareness and high device costs are market restraints.
Software and Services, Instruments, Kits, and Reagents Are the Main Products Of Flow Cytometry
The market for flow cytometry is divided into software and services, instruments, kits, and reagents. In the global flow cytometry market, the instruments category is the most lucrative of these types. The market share of flow cytometry reagents has increased as a result of the increased use of reagents in clinical trials and research, expanding the scope for applications for flow cytometry technology.
Reagents & consumables are wanted to rise as the dominant segment as they are important in flow cytometry analysis. The goal of the drive was to provide the organization with new opportunities for learning. Cost adequacy increased exactness, and convey capability is brought about by these innovations, which are likely to open up new opportunities for development in the future. Small measured high-throughput cytometers are likely to gain recognition in the near future. This is because of the combined benefits, such as cost viability and ease of use.
During the estimated years, the product fragment is expected to experience a significant rate of development. In the flow cytometry reagents market the product is used to control and acquire data generated by cytometers, analyze the data, and provide measurable results analysis. The product is used to collect cells and look at data for research, while in clinical analysis, it is used to find diseases by dissecting patient examples.
Researchers in a variety of fields, including oncology, virology, immunology, and irresistible illness checking, can benefit from this software component’s ability to perform superior analyses with shorter turnaround times. Additionally, the variety of flavors and scents offered by manufacturers has significantly increased, resulting in increased demand.
During the forecast period, the segments based on cell-based flow cytometry expand at the fastest rate
Cell-based flow cytometry and bead-based cytometry are the two types of technology that comes under this category. Its strength is being maintained by growing awareness of the advantages of cell-based research and a growing interest in early research. In addition, it is anticipated that mechanical advancements in cell-based measures, such as advancements in programming, instruments, calculations, partiality reagents, and names, will soon drive the reception.
It is anticipated that the segment using bead-based flow cytometry segment will expand more rapidly. Different intracellular solvent proteins, such as development factors, cytokines, chemokines, and phosphorylated cell proteins, can be measured using beads-based flow cytometry. For directing multiplex bead-based tests, the concluded flow cytometry procedure is considered the ideal apparatus. The multiplex bead-based method has a lot of potential for growth in the investigation, diagnosis, and treatment of resistant diseases.
Hospital and Clinics Segment Dominating the Flow Cytometry Market
The end users for flow cytometry are divided into hospitals and clinics, academic and research institutes, pharmaceutical companies, and biotechnological companies based on end-user. The hospitals and clinics are anticipated to be the most lucrative among these end-users in the global flow cytometry market over the forecast period. In cell science and molecular diagnostics, the method is used to quantify cell boundaries like cell type, cell heredity, and development stage, as well as the actual properties of cells and the recognition of biomarkers with clear antibodies.
The section is anticipated to exhibit significant development during the conjecture time period due to expanding R&D activities with flow cytometry. In the coming years, the clinical testing labs market is expected to expand at the fastest rate. This is due to the growing need for financially responsible treatment of specific diseases like cancer. It plays a significant role in the diagnosis and treatment of immunodeficiency and malignant tumors. The majority of people would agree that the rising acceptance of flow cytometry malignant growth and persistent illnesses will drive interest in demonstrative tests in clinical testing labs over the predictable period.
Key Market Segments
Based On Product Type
- Kit and Reagent
- Software and Services
Based on Technology
- Cell-based Cytometry
- Bead-based Cytometry
Based on End-User
- Hospitals and Clinics
- Academic and Research Institutes
- Biotechnology Companies
Technological Advancement in Flow Cytometry Instruments Is Projecting Market Growth
Technological advancements and the global adoption of flow cytometry in a variety of research and diagnostic applications are driving the market’s expansion. The market share of flow cytometry has also increased as new research applications like cytogenetics, proteomics, and marine biology have adopted the technology. Numerous prominent players’ increased R&D efforts for the development of advanced analytical reagents and multicolor assays are driving the market.
The rising incidence of chronic diseases has led to a rapid expansion of the flow cytometry market. Another factor driving the use of flow cytometry techniques is the rising global incidence of infectious diseases. Examples of typical samples include a GFP-producing cell line to various cell populations isolated from tissues.
Key factors driving the flow cytometry market growth include the rising R&D investments in the biotechnology sector and technological advancements in the field of flow cytometry for introducing new and improved analytical tools, such as microfluidic flow cytometry, for point-of-care testing.
High Product Cost
In order to carry out multiple research projects simultaneously, the majority of end users, which include pharmaceutical companies, major research institutions, and clinical labs, require a large quantity of flow cytometry equipment. Therefore, these devices’ initial costs for purchase and maintenance significantly rise. It is difficult for academic and research laboratories to purchase such tools due to financial barriers. Maintenance fees and a variety of other indirect costs also add to the overall cost of purchasing these products. However, the high cost of the flow cytometry market is anticipated to constrain the instruments.
Rise in Adaption of Flow Cytometry Approach Academic And Research
The expanding healthcare sectors in a number of emerging economies, including China, India, Brazil, and South Africa, are also contributing to the expansion of the flow cytometry market. The need to improve the healthcare industries in these nations is driven by the rapidly expanding geriatric population, increasing per capita incomes, high patient volumes, and rising awareness among the general public. As a result, governance in these economies is expanding its funds into healthcare infrastructure and facilities. Increasing investment in the flow cytometry sector is anticipated to provide market growth opportunities due to the numerous healthcare applications of its products.
With the development of assays for the detection of disease and the evaluation of drug resistance, the significance of flow cytometry workflow in the process of determining a patient’s prognosis for cancer patients has increased. The need for flow cytometry to determine prognosis is expected to rise over the next few years as the number of cancer cases rises.
The clinical diagnostic market is anticipated to expand at the quickest rate due to the benefits of flow cytometry in disease detection, such as quicker and more precise results, and the growing demand for affordable disease diagnosis. In addition, it is anticipated that the growth of flow cytometry industry will expand more rapidly as a result of the rising incidence of chronic diseases like HIV and cancer and the growing demand for sophisticated healthcare facilities
North America Dominated Largest Shares In Flow Cytometry Market
The flow cytometry market growth is expected to be dominated by the United States within North America. This domination is due to the universal use of scientifically developed flow cytometry solutions, the high cost of healthcare, and the standard healthcare infrastructure in the United States. This can be attributed to the growing priority that businesses are placing on the development of novel products, which are anticipated to provide new growth opportunities, and to the expansion of research and development, which is driving market expansion.
The rising incidence of cancer in the United States is encouraging the expansion of the flow cytometry market in the region. Additionally, there is a significant requirement for advanced flow cytometry solutions for research needs due to the presence of established pharmaceutical companies and universal research activities carried out by research universities. However, the Asia-Pacific flow cytometry industry is anticipated to take the lead during the forecast period.
This is primarily due to major international corporations outsourcing their research procedures to Asia-Pacific contract research organizations. In addition, it is anticipated that the flow cytometry industry will expand more rapidly as a result of the rising incidence of chronic diseases like HIV and cancer and the growing demand for cultured healthcare facilities.
- North America
- The US
- Western Europe
- The UK
- Rest of Western Europe
- Eastern Europe
- The Czech Republic
- Rest of Eastern Europe
- South Korea
- Australia & New Zealand
- Rest of APAC
- Latin America
- Costa Rica
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- United Arab Emirates
- Rest of MEA
Key Players Analysis
In order to grow flow cytometry businesses in international markets, emerging key players are concentrating on a variety of strategic policies. A number of companies like Sysmex Corporation, Luminex Corporation, Sartorius AG, Danaher Corporation, Becton Dickinson and Company, BioLegend, Inc., bioMérieux SA, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Danaher, Enzo Life Sciences, Inc. and others in the flow cytometry market are focusing on expanding their existing facilities for research and development.
Through investments, mergers, and acquisitions, businesses in the market for bio-based disinfectants are also developing new products and portfolio expansion strategies. In order to expand its market presence in India, BD Life Sciences sent a focal point of excellence in flow cytometry to the country in collaboration with Vellore Christian Clinical School.
The market for flow cytometry is segmented by a large number of local and regional players. Market players face intense competition from major market players, particularly those with extensive distribution networks and well-known brands. Companies have developed a variety of expansion strategies, including product launches and partnerships, to stay ahead of the market
Listed below are some of the most prominent flow cytometry industry players.
Market Key Players
- Danaher Corp.
- Becton, Dickinson, and Company (BD)
- Sysmex Corp.
- Agilent Technologies, Inc.
- Apogee Flow Systems Ltd.
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- Stratedigm, Inc.
- DiaSorin SPA
- Other Key Player
- June 2022: At the Universal Society for Growth of Cytometry (ISAC) CYTO 2022 conference with Becton, Dickinson, and Company made the debut of a new cell organizing technology. Research and the development of cell-based therapeutics in a collection of fields, including virology and oncology, along with a group of disease states, could be transformed by this new technology, which enables researchers to see and variety of cells at speeds never before possible.
- August 2021: The brand new benchtop cell analyzer known as the BD FACSymphony A1 Cell Analyzer was revealed by Becton, Dickinson, and Company. It is anticipated that labs of all sizes will benefit from the advanced flow cytometry capabilities offered by the fluorescence-activated cell analyst.
Report Features Description Market Value (2022) USD 51.6 Bn Forecast Revenue (2032) USD 104.4 Bn CAGR (2023-2032) 7.5% Base Year for Estimation 2022 Historic Period 2016-2022 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Product Type (Instrument, Kit and Reagent, Software, and Services); By Technology (Cell-Based Cytometry and Bead-Based Cytometry); By End-User (Hospitals and Clinics, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies) Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; the Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA Competitive Landscape Danaher Corp., Becton, Dickinson, and Company, Sysmex Corp., Agilent Technologies, Inc., Apogee Flow Systems Ltd., Bio-Rad Laboratories, Inc, Thermo Fisher Scientific, Inc., Stratedigm, Inc., DiaSorin SPA, Other Key Player Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)
Frequently Asked Questions (FAQ)What is the size of the flow cytometry market in 2021?
The flow cytometry Market size is US$ 6,863 million in 2021.What is the projected CAGR at which the flow cytometry market is expected to grow at?
The flow cytometry Market is expected to grow at a CAGR of 9.3% (2023-2032).List the segments encompassed in this report on the flow cytometry market?
Market.US has segmented the flow cytometry Market by geographic (North America, Europe, APAC, South America, and Middle East and Africa). By Product, the market has been further divided into Instruments, Software, and Other Products. By Technology, the market has been further divided into Cell-based and Bead-based. By Application, the market has been further divided into Industrial, Research, and Clinical. By End-Use, the market has been further divided into Commercial Organizations, Hospitals, Academic Institutes, and Clinical Testing Labs.List the key industry players of the flow cytometry market?
Danaher Corporation, Dickinson and Company, Luminex Corporation, Agilent Technologies, Inc., Miltenyi Biotec, Sysmex Corporation, Stratedigm, Inc., Apogee Flow Systems Ltd., Sony Biotechnology, Inc., Thermo Fisher Scientific, Inc., and other key players engaged in the flow cytometry market.Which region is more appealing for vendors employed in the flow cytometry market?
North America is expected to account for the highest revenue share of 41.1%. Therefore, the flow cytometry industry in North America is expected to garner significant business opportunities over the forecast period.Name the key areas of business for flow cytometry?
The US, India, China, Canada, UK, Japan, & Germany are key areas of operation for the flow cytometry market.Which segment accounts for the greatest market share in the flow cytometry industry?
With respect to the flow cytometry industry, vendors can expect to leverage greater prospective business opportunities through the cell-based segment, as this area of interest accounts for the largest market share.
- • Danaher Corporation • Dickinson and Company • Luminex Corporation • Agilent Technologies, Inc. • Miltenyi Biotec • Sysmex Corporation • Stratedigm, Inc. • Apogee Flow Systems Ltd. • Sony Biotechnology, Inc. • Thermo Fisher Scientific, Inc. • Other Key Players
| Single User|
USD / per unit
| Multi User|
USD / per unit
| Corporate User|
USD / per unit
|Report Library Access|
|Data Set (Excel)|
|Company Profile Library Access|
|Free Custumization||No||up to 10 hrs work||up to 30 hrs work|
|Accessibility||1 User||2-5 User||Unlimited|
|Analyst Support||up to 20 hrs||up to 40 hrs||up to 50 hrs|
|Benefit||Up to 20% off on next purchase||Up to 25% off on next purchase||Up to 30% off on next purchase|
|Buy Now ($ 3,499)||Buy Now ($ 4,299)||Buy Now ($ 4,999)|